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ABSTRACT
Objectives: To describe our experience of using a
confidentiality waiver (Section 251) in the National
Health Service (NHS) Act to identify and recruit
potential research participants to a cohort study and
consider its use in a wider research context.
Design: Methodological discussion.
Setting: NHS Trusts in England.
Methods: We established a research recruitment
process with quality health (QH), administrators of the
National Cancer Patient Experience Survey, after an
amendment to a Section 251 approval (reference
number ECC-8-05d-2011). NHS Trusts agreeing to
implement the process were requested to send the
details of 16–24-year-olds, identified by a relevant
ICD-10 code indicating a cancer diagnosis within a
specified time period to QH. QH sent study information
and a consent-to-be-contacted form which allowed QH
to send details to BRIGHTLIGHT, for BRIGHTLIGHT to
contact the treating team confirming eligibility and for
an interviewer from Ipsos MORI to contact them.
Written consent was to be obtained at interview.
Results: The method was implemented in 98 trusts;
75 supplied patient details. QH sent information to 441
young people, of whom 64 (15%) responded. Of these,
23 had already consented to participate. Adverse events
were reported by 6 (1%) invitees: 4 were distressed
because they did not have cancer, their details being
submitted to QH due to incorrect hospital coding, and 1
young person was distressed about their diagnosis and
requested no further contact and 1 young person found
out they had cancer from the invitation.
Conclusions: Application of Section 251 of the NHS
Act (2006) to directly approach participants can
facilitate recruitment to research projects where
routinely collected NHS data are available to select
eligible patients. The benefits of this method are that it
requires fewer resources to recruit across multiple sites,
and is quicker. Further information on the impact on
bias and adverse event profile are required.
INTRODUCTION
Despite national policies aimed to promote
research in the National Health Service
(NHS), a large number of research studies
do not recruit to target or within the pre-
dicted time frame.1 This can have adverse
impact on costs, the timeliness and relevance
of the research questions and the signiﬁ-
cance of evidence generated.2 With increas-
ing ﬁnancial pressures on the NHS and
reduced availability of funding for research,
the impact of suboptimal recruitment to
studies is evident; If recruitment has to be
extended to reach the required sample size,
the trial will cost more and take longer,
delaying the use of the results in clinical
practice. If trials become more expensive
and take longer, fewer trials can be con-
ducted overall with the limited funding and
resources available.3 More recently, further
attention has been given to increasing the
value of research and reducing waste which
includes increasing the efﬁciencies of recruit-
ment and retention in studies.4 There is a
substantial body of evidence around recruit-
ment to clinical trials; however, the problems
of recruiting to other types of study are also
described.5 A previous study illustrated that
less than a third (31%) of cohort studies
based in the UK achieved their recruitment
target1 and under-recruitment appears to be
universal across country, study design and
clinical area.6 7
Strengths and limitations of this study
▪ This method could be applied to recruit to
low-risk research.
▪ The increase in the availability of routinely col-
lected data in the National Health Service (NHS)
makes the method applicable to multiple
indications.
▪ This method is cost-effective.
▪ This method may reduce the bias introduced by
intermediaries in the recruitment process.
▪ The method is dependent on data accuracy in
NHS Trust returns.
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The role of the healthcare professionals is central to
facilitating participation in research. However, an alter-
native role, as a barrier to recruitment, is beginning to
be realised.8 9 Professional gatekeeping or paternalism is
not wholly understood, but its origins may lie within a
sense of responsibility to protect patients from perceived
harm.9 In the study by Borschmann et al,8 gatekeepers
are described as basing referral to research on criteria
other than those speciﬁed in the study protocol and
making assumptions on suitability based on their esti-
mate of the likelihood of the potential participant
accepting their assessment of the beneﬁt of the research
and the predicted impact on their clinical relationship.
A further example of professional gatekeeping
emerged during BRIGHTLIGHT, a National Institute
for Health Research (NIHR)-funded cohort study, which
aimed to recruit 2012 young people with cancer over
18 months. BRIGHTLIGHT was designed with the assist-
ance of young people with cancer and in conjunction
with healthcare professionals. It is the largest study con-
ducted for teenagers and young adults with cancer and
poses the question ‘Do specialist Cancer Services for
teenagers and young adults add value?’. The study pro-
vided evidence for existing health policy that advocates
specialists ‘age-appropriate’ care for young people.
Healthcare models for this group have arisen without a
substantial pre-existing research evidence base and the
holistic multidisciplinary approach to care for teenagers
and young adults (TYA) in the UK was becoming under
increasing pressure and international scrutiny to provide
evidence for effectiveness and costs. Critically, four key
points around ‘age-appropriate’ specialist services
remained unanswered. (1) What is specialist care for
young people? (2) Does specialist care improve out-
comes for young people with cancer? (3) What are the
key components of specialist care? (4) How much does
specialist care cost the NHS, young people and their
families? The study is organised in four workstreams and
six interrelated studies of which the longitudinal cohort
constitutes the major component of the study (http://
www.brightlightstudy.com).
BRIGHTLIGHT was designed around the ‘5A’ princi-
ples9 10 and included a substantial period of feasibility
work with patients and engagement with key stake-
holders.11 The 5As principles set out a strategy to maxi-
mise opportunities for the young people with cancer
to participate in research studies. However, the princi-
ples are relevant to other populations. Improved partici-
pation opportunities are possible when studies are
‘Appropriate’ in that the eligibility criterion, including
age, is permissive of the inclusion of the popula-
tion being studied, in this case, TYA. The age eligibility
criterion of BRIGHTLIGHT was to include those aged
13–24 years at diagnosis in keeping with the service con-
ﬁgurations that were being examined. The ‘Availability’
and ‘Access’ of the study is key to recruitment.
BRIGHTLIGHT was conducted in the majority of NHS
Trusts (over 100) in England and included all 13 princi-
pal (specialist) treatment centres for young people’s
cancer. The ‘Acceptability’ of the research question is
also essential to successful inclusion. If studies are
deemed irrelevant or poorly designed by healthcare pro-
fessionals, they are unlikely to offer the study to patients
and similarly if the questions are not relevant for
patients or the study procedures are unpleasant or
lengthy, refusal to participate is more likely. We designed
BRIGHTLIGHT with young people and healthcare pro-
fessionals, working together to optimise study design
and outcomes.10 The ﬁfth A, ‘Awareness’, relates to pro-
fessional and patient awareness of a study and the
importance of offering access. Prior to opening, we
embarked on a nationwide ‘Awareness’ campaign that
included professional and patient conferences, network
managers and social media campaigns. Consequently,
from inception, the study had national support and
engagement from patients, research networks, health-
care professionals and relevant charitable bodies.
Despite this level of engagement, recruitment to the
study fell below that expected, requiring multiple proto-
col amendments to introduce changes aimed at facilitat-
ing study entry, a recruitment extension of 12 months
and a reduction of the planned sample size with the
acceptance of lower statistical power.
Screening logs were requested from each participating
Trust to explore reasons for lower than anticipated
recruitment. This was to rule out patient refusal as the
primary cause. Our anticipated refusal rate had been
35% based on the previously published studies in this
population;12–14 however, the screening logs showed an
actual refusal rate of 22%. Further analysis of the screen-
ing logs illustrated that 42% of potentially eligible
patients had not been approached regarding the study.
Reasons for exclusion cited on the screening logs
included many that were not protocol exclusion criteria.
The screening logs identiﬁed that young people
appeared to have limited access to the study even in
Principal Treatment Centres. We therefore sought alter-
native methods of recruitment that might reduce the
need for healthcare professional input. Consultation
with the BRIGHTLIGHT patient and public involvement
group regarding access to research suggested support
for receiving a direct invitation to participate in
research.9 One such method was then identiﬁed that
had been used routinely with patients in the NHS for
several years, including young people with cancer.
Section 251 of the NHS Act (2006) in the UK enables
the Secretary of State for Health to set aside the
common law duty of conﬁdentiality for deﬁned medical
purposes. It was recognised that some activities within
the NHS, including research, required identiﬁable
patient information, but obtaining consent to use this
information was not always possible. Applications to
access patient information are required to show due
regard for the eight principles of the Data Protection
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Act (1998) and demonstrate that there is no other way
of involving patients without this direct approach. We
describe our experience of using Section 251 to identify
and recruit potential research participants to a cohort
study, and discuss its potential for use in a wider
research context.
METHODS
NHS patient experience surveys
There are a number of patient experience surveys admi-
nistered annually in the NHS, which are managed by
commercial research companies contracted to the
NHS.15 Recruitment to the National Cancer Patient
Experience Survey (NCPES) is coordinated by Quality
Health (QH).16 Every year, over a 3-month period,
patients who have been discharged following an
in-patient or day case admission are identiﬁed through
hospital Patient Administration Systems (PAS). Patients
are eligible for inclusion if they are aged 16 or over and
have a primary diagnosis of cancer indicated by the rele-
vant ICD-10 code. Each NHS Trust has a designated
Survey Lead who is responsible for checking the list of
patients to ensure those who have died are not included
and they have an appropriate ICD-10 code before sub-
mitting the data through secure data transfer systems to
QH. A second level check for mortality is undertaken at
QH before postal copies of the NCPES are sent to
patients.17 This process has been implemented since
2010, with improvements in practice being introduced
over time to ensure that patients are not inappropriately
contacted, for example, ICD-10 codes are no longer allo-
cated to patients until there is a conﬁrmed diagnosis of
cancer.
Application of the method to BRIGHTLIGHT
We worked with QH on an adapted version of the
method used for the NCPES. A prior risk assessment for
this process suggested that there would be minimal risk
to patients but where low or medium risk was identiﬁed,
processes could be implemented to protect their safety
(table 1). BRIGHTLIGHT already had Section 251
approval in place to enable the Cancer Waits data set to
be used to identify patients eligible for the cohort
(ECC-8-05d-2011). An amendment was approved by the
Health Research Authority (HRA) to allow patient
details being transferred to QH without their consent
(ﬁgure 1).
We prepared information about the study to send dir-
ectly to young people to allow them to agree in principle
to take part. The information pack contained a study
leaﬂet and contact form with details of a freephone
number if they required further information. The
contact form was for young people to agree to their
details being sent to the BRIGHTLIGHT team, for their
healthcare team to be contacted (to double check for
exclusion criteria) and for their details to be sent to
Ipsos MORI, the research organisation undertaking the
interviews, who would obtain signed consent at the time
of interview. The exclusion criteria check was to identify
if any young person were in prison, and if young people
had advanced disease, to ensure they would still be alive
at the time of interview.
The guidance sent to NHS Trusts requested details of
patients aged 16–24 years with a new cancer diagnosis,
indicated by the relevant ICD-10 codes. The same
process of drawing and checking the sample used for
the NCPES was applied. Four data extraction requests
were planned for patients diagnosed between July and
September, October, November and December 2014.
RESULTS
Principal investigators for the 104 Trusts which were
open to recruitment were informed that this process was
going to be implemented. No objections were raised.
After gaining HRA and Research Ethics Committee
approval, four Research and Development (R&D)
departments objected to the amendment without speci-
fying a reason, one R&D would not approve the amend-
ment because the sample would be small and therefore
they would be identiﬁable from young people’s
responses (the Trust was open to recruitment using exist-
ing mechanisms) and one R&D would not accept the
Section 251 approval and insisted on the completion of
numerous lengthy documents for an internal
Information Governance review. This Trust was excluded
from participating. QH therefore made sample requests
to 98 NHS Trusts.
While 75 Trusts responded to the initial sample
request for patient details, only 57 trusts supplied
patient details by the fourth request. No data were sub-
mitted by 18 Trusts. Details of 441 young people were
returned, of whom 64 (15%) agreed to be contacted by
an interviewer (table 2). Of these, 23 had already con-
sented to BRIGHTLIGHT through established mechan-
isms. Seven young people actively refused to be
contacted further, 352 [young people did not respond]
5 were returned by Royal Mail as having moved, 3 were
identiﬁed as having died and 7 patients were ineligible
for the study. A further three young people could also
not be included because information was not returned
by their treating Trust to ensure that they were deﬁnitely
eligible for participation.
A total of six young people/parents raised concerns
with the BRIGHTLIGHT team and QH after receiving
information. Four young people’s details had been sub-
mitted based on having cancer when they did not have a
QH’s cancer diagnosis due to incorrect hospital coding,
one young person found out through receiving informa-
tion that he had cancer and one young person who was
distressed about their cancer diagnosis did not want to
receive any further information. All their healthcare
teams were contacted to provide appropriate support
and reassurance to young people.
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Table 1 Risk assessment for the NCPES-based recruitment method
Potential risk Action to limit or resolve risk
Risk
rating
Inappropriate patients are identified by NHS Trusts Trusts to be given a guidance manual with clear criteria
for selecting patients. Based on the NCPES—holding
codes are no longer used, so patients given an ICD-10
code will have cancer
Low
Young people who have died are contacted to
participate
Quality Health under take DBS checks to remove
deceased patients
Low
Patient identifiable data from NHS Trust that is being
used without patient consent being transferred
incorrectly
Data transfer using the methods that exist for the
NCPES, which Trusts are familiar with
Low
Contact forms being sent to incorrect address Only the addresses provided by the NHS Trust will be
used
Low
Young persons do not know they have cancer BRIGHTLIGHT and Quality Health have advice lines for
young people to contact if they have any concerns about
the study. Links would be made to the clinical team to
provide appropriate support
Low
Contact forms do not get returned by post Follow-up letters to be sent on two occasions Medium
Recruiting Trusts stop recruiting using standard
methods because the NCPES-based method is
viewed as a replacement
Letter to be sent to principal investigators explaining why
this method is being used in conjunction with existing
routes to recruitment
Medium
Young people are approached twice about the study Covering letter with the information pack to state that if
they have already been contacted/consented to
BRIGHTLIGHT to return the letter in the envelop
provided so they do not receive reminder letters
Medium
Young people have been transferred to another Trust,
so it is not possible to confirm eligibility
The BRIGHTLIGHT team have a network of contacts
across recruiting Trusts so they would identify the Trust
the young person has been transferred to and contact
the team there. If the identifying Trust does not know the
location of where the young person has been transferred
to, this information will be sought from the North West
Knowledge Intelligence Team under the existing Section
251 approval
Low
Young people have been transferred to a Trust that is
not recruiting to BRIGHTLIGHT
The BRIGHTLIGHT team would contact the Principal
Treatment Centre to determine whether they would be
able to confirm eligibility (from their MDT information).
If eligibility can be confirmed, the young person will be
invited to participate as detailed in the protocol. If
eligibility cannot be confirmed, the BRIGHTLIGHT team
will contact young people to explain the error and will
offer them a place in the YAP, the BRIGHTLIGHT user
group
Low*
Patients are found to be not eligible after the contact
form has been returned and checks made with the
clinical team by the BRIGHTLIGHT team
The BRIGHTLIGHT team will contact the young person
to explain the error. If young people have a cancer
diagnosis, they will be offered a place in the YAP
Low
Consent forms are not returned to the BRIGHTLIGHT
team after the young person has been interviewed
Ipsos MORI field interviewers will receive additional
training and will return the consent form with their
contact records when the interview is complete
Low
A high attrition rate by young people recruited by this
method
There is a dropout rate between recruitment and data
collection at the first wave of 25%. Potentially there may
be a higher rate of dropout if information has not been
given face-to-face. There is insufficient evidence to
quantify this and therefore the BRIGHTLIGHT team and
Ipsos MORI will monitor dropout (and subsequent
attrition at waves 2–5) in this group separately from the
rest of the cohort
Low†
*If a Trust is not participating, then information required in the case report form may not be obtainable, so there will be the potential for
missing data. This is anticipated as being low risk.
†Risk to data collection and not to young people.
DBS, Demographics Batch Service; NCPES, National Cancer Patient Experience Survey; YAP, Young Advisory Panel.
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DISCUSSION
We have tested a method for directly contacting patients
to request participation in a low-risk research study
which had broad inclusion criteria. It has potential for
use by researchers in other ﬁelds. The uptake rate of
15% appears low and ranged from 10% to 22% between
samples. Although low, young people are typically
deﬁned as a ‘hard to reach’ population for researchers
and this method was implemented with no national
advertising through NHS trusts or social media typically
frequented by young people. The NHS Cancer
Experience Patient Survey is accompanied by wide-
spread advertising in trusts with a response rate of
around 35% in young people rising to 60% for those
Figure 1 Schematic
representation of the
NCPES-based method for
recruitment. DBS, Demographics
Batch Service; NCPES, National
Cancer Patient Experience
Survey; NHS, National Health
Service.
Table 2 Summary of Trust involvement and data returned
Trust involvement, n (%) Sample returned, n Response, n (%)
Sample 1: July to September 75 (76.5) 213 21 (9.9)
Sample 2: October 69 (70.4) 102 22 (21.6)
Sample 3: November 59 (60.2) 55 8 (14.5)
Sample 4: December 57 (58.2) 71 13 (18.3)
Total 441 15 (14.5)
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aged 65–70 indicating that with appropriate publicity in
place prior to recruitment will enhance the potential to
recruit to studies by this method.
Although 35% of young people aged 16–24 years
return the NCPES in our experience of working with
young people, requesting information to be returned
through the post has limited success. Previous work we
have carried out with young people regarding optimis-
ing recruitment methods to research studies supported
this: ‘If I was posted a letter to take part in a study I
might not be as pro-active in replying and sending
back’.5 It could be assumed that obtaining consent via
electronic methods may have resulted in a higher
return; however, we implemented this process rapidly as
a ‘quick-ﬁx’ remedy to ensure that the target sample size
was achieved and time and resource constraints pre-
vented us exploring other electronic methods for
gaining young people’s consent. Additional consenting
methods more appropriate to the age group are worthy
of consideration in future studies to maximise opportun-
ities for young people to participate.
When we asked young people what types of research it
would be appropriate to contact them by post, they
agreed it would be acceptable for most non-drug study
types and, if it was supported with dialogue with health-
care professionals, also for treatment-related studies.9
This supports work undertaken by the HRA patients’
desire to have the option of choosing whether or not to
take part in research.18 The NIHR launched the ‘Okay to
ask’ campaign in 2014 encouraging patients to ask
healthcare professionals about available research.19
However, recent evaluation of this campaign has shown
that although 95% of patients felt it was important to ask
about research, only 21% said they felt comfortable to do
so.20 This method presents an opportunity to present
available research to patients mitigating any barriers
which may be perceived between patients and/or profes-
sionals about approaching the topic of research.
As discussed previously, the need for rapid implemen-
tation meant that there was limited advertising within
Trusts, mostly relying on dialogue with the principal
investigators and R&D departments. Formal letters to
Chief Executives, advertising materials for relevant
departments and links between the BRIGHTLIGHT
team and Survey Leads, rather than QH, might have
facilitated samples to be drawn from all Trusts to which
requests were made. With this in mind, the total cost of
implementation was £5500, equating to £86 per patient,
slightly higher than the £50 NHS support cost that had
been calculated for recruitment. Greater promotion of
the method and its use in different populations might
increase uptake rates and so reduce the cost per capita
recruited.
The small number of young people who were con-
tacted inappropriately indicates a limitation of this
method. Some Trusts continue to use ICD-10 codes
before diagnostic investigations are complete and some
lists were returned to QH without the appropriate
checks having been undertaken. By engaging a research
organisation with extensive experience of this method,
the incidence of error was small (1.4%) and having a
robust mechanism in place to support those young
people affected by errors ensured that any problems
were addressed promptly with patients.
In conclusion, application of Section 251 of the NHS
Act (2006) to directly approach participants can facili-
tate recruitment to research projects where routinely col-
lected NHS data are available to identify eligible patients
for the study. The beneﬁts of this method are that it
requires fewer resources to recruit across multiple sites
and is quicker. The method may also overcome selection
bias introduced by recruitment intermediaries; however,
this is a matter that requires further exploration. If this
method were to be applied in conjunction with wide-
spread advertising as described above, it may be that the
level of publicising within trusts would vary as would pro-
motion to certain groups of patients to encourage par-
ticipation when the invite arrives, and this may
introduce additional bias. Overall, it is an approach that
warrants consideration for other studies.
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